Maintenance of sphingolipid homeostasis is critical for cell growth and programmed cell death (PCD). Serine palmitoyltransferase (SPT), composed of LCB1 and LCB2 subunits, catalyzes the primary regulatory point for sphingolipid synthesis. Small subunits of SPT (ssSPT) that strongly stimulate SPT activity have been identified in mammals, but the role of ssSPT in eukaryotic cells is unclear. Candidate Arabidopsis thaliana ssSPTs, ssSPTa and ssSPTb, were identified and characterized. Expression of these 56-amino acid polypeptides in a Saccharomyces cerevisiae SPT null mutant stimulated SPT activity from the Arabidopsis LCB1/LCB2 heterodimer by >100-fold through physical interaction with LCB1/LCB2. ssSPTa transcripts were more enriched in all organs and >400-fold more abundant in pollen than ssSPTb transcripts. Accordingly, homozygous ssSPTa T-DNA mutants were not recoverable, and 50% nonviable pollen was detected in heterozygous ssspta mutants. Pollen viability was recovered by expression of wild-type ssSPTa or ssSPTb under control of the ssSPTa promoter, indicating ssSPTa and ssSPTb functional redundancy. SPT activity and sensitivity to the PCD-inducing mycotoxin fumonisin B 1 (FB 1 ) were increased by ssSPTa overexpression. Conversely, SPT activity and FB 1 sensitivity were reduced in ssSPTa RNA interference lines. These results demonstrate that ssSPTs are essential for male gametophytes, are important for FB 1 sensitivity, and limit sphingolipid synthesis in planta.

Sphingolipids are membrane and bioactive lipids that are required for many aspects of normal mammalian development and physiology. However, the importance of the regulatory mechanisms that control sphingolipid levels in these processes is not well understood. The mammalian ORMDL proteins (ORMDL1, 2 and 3) mediate feedback inhibition of the de novo synthesis pathway of sphingolipids by inhibiting serine palmitoyl transferase in response to elevated ceramide levels. To understand the function of ORMDL proteins in vivo, we studied mouse knockouts (KOs) of the Ormdl genes. We found that Ormdl1 and Ormdl3 function redundantly to suppress the levels of bioactive sphingolipid metabolites during myelination of the sciatic nerve. Without proper ORMDL-mediated regulation of sphingolipid synthesis, severe dysmyelination results. Our data indicate that the Ormdls function to restrain sphingolipid metabolism in order to limit levels of dangerous metabolic intermediates that can interfere with essential physiological processes such as myelination.

Journal of Lipid Research Volume 55, 20142521 the metabolic pathway ( 3 ). Ceramide undergoes anabolic reactions to generate sphingomyelin and various glycosphingolipids, or catabolic reactions, which lead to the generation of sphingosine and sphingosine-1-phosphate (S1P). Alterations in ceramide metabolism have been implicated in many pathophysiologies, including aging ( 4-6 ), neurodegeneration ( 7,8 ), metabolic diseases ( 9-15 ), cancer (16)(17)(18)(19)(20), and stress responses ( 5 ). However, the mechanisms that regulate cellular ceramide levels under physiologic and pathophysiologic conditions are still not well-understood.Changes in the levels of ceramide and other sphingolipid metabolites have been shown to affect macroautophagy (referred to hereafter as autophagy) in a variety of cell types ( 21-27 ). Autophagy is a catabolic process that starts with the generation of a double-membrane cup-like phagophore from the ER or other sources ( 28, 29 ); the phagophore then captures cellular material and matures into an autophagosome that will subsequently fuse with a lysosome to form an autolysosome, enabling degradation of the engulfed material. This process is crucial for removal of pathogens and damaged proteins and organelles, as well as for the reutilization of nutrients to generate energy and maintain homeostasis. Clearance of toxic or defective cellular components protects from degenerative, metabolic, and infl ammatory diseases ( 30 ). Some forms of autophagy are specifi c, uniquely targeting mitochondria (mitophagy) ( 31 ), segments of the ER (ER-phagy or reticulophagy) ( 32 ), or triglyceride stores (lipophagy) ( 33 ) for degradation. Impaired autophagy is encountered, along with increased ceramide levels, in a number of pathophysiologic conditions, including aging ( 34, 35 ), neurodegeneration ( 36, 37 ), obesity ( 10 ), and type 2 diabetes ( 9 ).Abstract Sphingolipid levels are tightly regulated to maintain cellular homeostasis. During pathologic conditions such as in aging, infl ammation, and metabolic and neurodegenerative diseases, levels of some sphingolipids, including the bioactive metabolite ceramide, are elevated. Sphingolipid metabolism has been linked to autophagy, a critical catabolic process in both normal cell function and disease; however, the in vivo relevance of the interaction is not wellunderstood. Here, we show that blocking autophagy in the liver by deletion of the Atg7 gene, which is essential for autophagosome formation, causes an increase in sphingolipid metabolites including ceramide. We also show that overexpression of serine palmitoyltransferase to elevate de novo sphingolipid biosynthesis induces autophagy in the liver. The results reveal autophagy as a process that limits excessive ceramide levels and that is induced by excessive elevation of de novo sphingolipid synthesis in the liver. Dysfunctional autophagy may be an underlying mechanism causing elevations in ceramide that may contribute to pathogenesis in diseases. Sphingolipids are a structurally and functionally di...

Sphingolipid biosynthesis generates lipids for membranes and signaling that are crucial for many developmental and physiological processes. In some cases, large amounts of specific sphingolipids must be synthesized for specialized physiological functions, such as during axon myelination. How sphingolipid synthesis is regulated to fulfill these physiological requirements is not known. To identify genes that positively regulate membrane sphingolipid levels, here we employed a genome-wide CRISPR/Cas9 loss-of-function screen in HeLa cells using selection for resistance to Shiga toxin, which uses a plasma membrane-associated glycosphingolipid, globotriaosylceramide (Gb3), for its uptake. The screen identified several genes in the sphingolipid biosynthetic pathway that are required for Gb3 synthesis, and it also identified the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor widely involved in development and physiology, as being required for Gb3 biosynthesis. AHR bound and activated the gene promoter of serine palmitoyltransferase small subunit A (SPTSSA), which encodes a subunit of the serine palmitoyltransferase that catalyzes the first and rate-limiting step in de novo sphingolipid biosynthesis. AHR knockout HeLa cells exhibited significantly reduced levels of cell-surface Gb3, and both AHR knockout HeLa cells and tissues from Ahr knockout mice displayed decreased sphingolipid content as well as significantly reduced expression of several key genes in the sphingolipid biosynthetic pathway. The sciatic nerve of Ahr knockout mice exhibited both reduced ceramide content and reduced myelin thickness. These results indicate that AHR up-regulates sphingolipid levels and is important for full axon myelination, which requires elevated levels of membrane sphingolipids.

No abstract

No abstract

Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disorder characterized by selective degeneration of lower and upper motor neurons leading to progressive muscle weakness, swallowing difficulties, and respiratory insufficiency that ultimately causes death usually within 2–5 years of diagnosis. The majority of ALS cases occur sporadically, but a significant number (>10%) display Mendelian inheritance. Very recently, four unique de novo or dominantly inherited SPTLC1 mutations associated with early childhood‐onset ALS without clinical sensory involvement have been identified in eight independent families. SPTLC1 encodes a subunit of serine palmitoyltransferase (SPT), the committed and rate‐limiting enzyme of sphingolipid synthesis. The ALS mutations flank the first membrane spanning domain of SPTLC1, which is not required for ER targeting, association with the SPTLC2 and ssSPT subunits, or enzymatic activity. Rather, this domain is critical for binding of the ORMDL proteins that negatively regulate SPT. This suggested that the SPTLC1 mutations might interfere with homeostatic regulation of SPT and that elevated de novo sphingolipid synthesis could underlie the ALS disease pathology. Our studies reveal that these highly penetrant SPTLC1 mutations do indeed abrogate negative regulation of SPT by the ORMDL proteins and result in elevated levels of sphingolipids. Using cultured cells, patient fibroblasts, iPSC‐induced MNs, and mouse models, we are investigating the importance of ORMDL regulation in the maintenance of sphingolipid homeostasis and the mechanisms responsible for sphingolipid mediated motor neuron death. Significantly, the ALS SPTLC1 mutations confer disease pathology by a distinctly different mechanism than the previously characterized SPTLC1 and SPTLC2 mutations associated with hereditary sensory and autonomic neuropathy type 1 (HSAN1). Whereas the ALS mutations result in elevated levels of canonical sphingolipids, the HSAN1 mutations, which compromise amino acid substrate selectivity of SPT, cause accumulation of atypical deoxy‐sphingoid bases that are implicated in neuronal cell death.

No abstract